Scholarlink

<p>The Verloes or Hale diagnostic criteria have been applied for diagnosing CHARGE syndrome in suspected patients. This study was conducted to evaluate the diagnostic rate of <i>CHD7</i> according to these diagnostic criteria in suspected patients and also to investigate other genetic defects in <i>CHD7</i>-negative patients. The clinical findings and the results of genetic testing of <i>CHD7</i>, chromosome microarray, exome sequencing, or genome sequencing of 59 subjects were reviewed. <i>CHD7</i> pathogenic variants were identified in 78% of 46 subjects who met either the Verloes or Hale diagnostic criteria and in 87% of 38 subjects who met both criteria, whereas no <i>CHD7</i> variant was detected in 13 subjects who met neither criterion. Among 23 patients without the <i>CHD7</i> variant, six genetic diseases were identified in 7 patients, including Wolf–Hirschhorn syndrome, 1q21 deletion syndrome, 19q13 microdeletion, and pathogenic variants in <i>PLCB4</i>, <i>TRRAP</i>, and <i>OTX2</i>. Based on these comprehensive analyses, the overall diagnostic rate was 73% for seven different genetic diseases. This study emphasizes the importance of comprehensive clinical and genetic evaluation in patients with clinically suspected CHARGE syndrome, recognizing the overlapping phenotypes in other rare genetic disorders.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Beyond CHD7 gene: unveiling genetic diversity in clinically suspected CHARGE syndrome

  • 期刊论文

  • 发表日期：

    2025年2月25日

查看全文
  • Dohyung Kim,
  • Ji-Hee Yoon,
  • Hyunwoo Bae,
  • Soojin Hwang,
  • Go Hun Seo,
  • June-Young Koh,
  • Young Seok Ju,
  • Hyo-Sang Do,
  • Soyoung Kim,
  • In Hee Choi,
  • Gu-Hwan Kim,
  • Ja Hye Kim,
  • Jin-Ho Choi,
  • Beom Hee Lee

摘要

The Verloes or Hale diagnostic criteria have been applied for diagnosing CHARGE syndrome in suspected patients. This study was conducted to evaluate the diagnostic rate of CHD7 according to these diagnostic criteria in suspected patients and also to investigate other genetic defects in CHD7-negative patients. The clinical findings and the results of genetic testing of CHD7, chromosome microarray, exome sequencing, or genome sequencing of 59 subjects were reviewed. CHD7 pathogenic variants were identified in 78% of 46 subjects who met either the Verloes or Hale diagnostic criteria and in 87% of 38 subjects who met both criteria, whereas no CHD7 variant was detected in 13 subjects who met neither criterion. Among 23 patients without the CHD7 variant, six genetic diseases were identified in 7 patients, including Wolf–Hirschhorn syndrome, 1q21 deletion syndrome, 19q13 microdeletion, and pathogenic variants in PLCB4, TRRAP, and OTX2. Based on these comprehensive analyses, the overall diagnostic rate was 73% for seven different genetic diseases. This study emphasizes the importance of comprehensive clinical and genetic evaluation in patients with clinically suspected CHARGE syndrome, recognizing the overlapping phenotypes in other rare genetic disorders.